Phase 4
Completed N=42
The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation
Source: ClinicalTrials.gov NCT02877485 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray) — 69.1; 68.5; 65.2; 65.8 score on a scale — p=0.7
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this project is to determine if intranasal corticosteroids have an effect on nasal obstruction in patients with nasal septal deviation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray) |
69.1; 68.5; 65.2; 65.8; 64.1; 61.5 | 0.7 |
| SECONDARY Nasal Obstruction Symptom Evaluation (NOSE) Score Following Surgery in Subset of Patients Who Elect to Undergo Surgery. |
70; 16.2; 17.6; 17.2; 22.2; 20 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Age greater than 18
- NOSE score greater than 55
- Nasal septal deviation on exam
Exclusion Criteria
- Intranasal steroid use within the last three months
- Current systemic steroid use
- Prior septal surgery
- Individuals who are pregnant or actively breastfeeding
Data sourced from ClinicalTrials.gov (NCT02877485). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.